Can I read Review of Immunosuppressive Usage in Pancreas Transplantation on EtoBox?

Review of Immunosuppressive Usage in Pancreas Transplantation by Robert J Stratta is a Medicine article available to read on EtoBox.

What is Review of Immunosuppressive Usage in Pancreas Transplantation about?

Throughout 1997, nearly 10 000 pancreas transplants have been performed worldwide, with 88% being simultaneous kidney transplants (SKPT). The current 1 yr patient survival rate exceeds 90% and pancreas graft survival (complete insulin independence) rate exceeds 80% for SKPT, 70% for sequential pancreas after kidney transplant (PAKT), and 65% for pancreas transplant alone (PTA). According to registry data, rejection accounts for 32% of graft failures in the first year after pancreas transplantation. However, improvements are expected to continue with the evolution of treatment protocols. Most pancreas transplant centers employ quadruple drug immunosuppression with anti‐lymphocyte induction with either a monoclonal or polyclonal antibody agent. In recent years, there has been an overall decline in the use of antibody induction therapy from 90% during the period 1987–1993 to 83% of pancreas transplants performed during 1994–1997. Maintenance immunosuppression is triple therapy consisting of a calcineurin inhibitor (cyclosporine or tacrolimus), corticosteroids, and an anti‐metabolite (AZA or MMF). Prior to 1995, nearly all pancreas transplant recipients were managed with Sandimmune. In

Who reads Review of Immunosuppressive Usage in Pancreas Transplantation?

Author

Robert J Stratta

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 0902-0063)

Published

1999

Language

EN

Field

Medicine (Health Sciences)